Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Pulmonary Hypertension?

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Dundee
• Collaborators: Chief Scientist Office of the Scottish Government; NHS Fife; NHS Tayside
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

• COPD

• Forced expiratory volume in 1 second (FEV1) <80% (FEV1/FVC <0.70)

• Right ventricular systolic pressure (RVSP) > 30 mmHg or Pulmonary Acceleration time <120 ms

Exclusion Criteria:

• Pulmonary stenosis or echo left ventricular outflow tract obstruction

• Left ventricular ejection fraction < 45%

• Patients taking nitrates, nicorandil or doxazosin.

• Drug contraindications:

• Systolic Blood Pressure <90 mmHg

• recent stroke

• unstable angina

• past history of non arteritic anterior ischaemic optic neuropathy